Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 1, 2009, Pages

  González, Germán E ^a   Seropian, Ignacio M ^a   Krieger, Maria Laura ^a   Palleiro, Jimena ^a   Lopez Verrilli, Maria A ^a   Gironacci, Mariela M ^a   Cavallero, Susana ^a   Wilensky, Luciana ^a   Tomasi, Victor H ^a   Gelpi, Ricardo J ^a   Morales, Celina ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiotensin II type 1 receptor blockers

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CD45RO ANTIGEN; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; ISOLATED HEART; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RECEPTOR BLOCKING; WOUND HEALING IMPAIRMENT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN; LOSARTAN; LYMPHOCYTES; MACROPHAGES; MUSCLE CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEUTROPHIL INFILTRATION; ORGAN SIZE; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; SURVIVAL ANALYSIS; VENTRICULAR REMODELING;

EID: 67650046164     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00498.2007     Document Type: Article

References (45)

1. Behr-Roussel D, Rupin A, Simonet S, Bonhomme E, Coumailleau S, Cordi A, Serkiz B, Fabiani JN, Verbeuren TJ. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation 102: 1033-1038, 2000.
2. 1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 19: 251-259, 2005.
3. Bogen DK, Rabinowitz SA, Needleman A, McMahon TA, Abelmann WH. An analysis of the mechanical disadvantage of myocardial infarction in the canine left ventricle. Circ Res 47: 728-741, 1980.
4. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 184: 940-943, 2001.
5. Cavasin MA, Tao Z, Menon S, Yang XP. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci 75: 2181-2192, 2004.
6. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001.
7. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828, 2006.
8. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360: 752-760, 2002.
9. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105: 2512-2517, 2002.
10. Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol 96: 10L-18L, 2005.
11. Gallagher AM, Bahnson TD, Yu H, Kim NN, Printz MP. Species variability in angiotensin receptor expression by cultured cardiac fibroblasts and the infarcted heart. Am J Physiol Heart Circ Physiol 274: H801-H809, 1998.
12. Gonzalez GE, Palleiro J, Monroy S, Perez S, Rodriguez M, Masucci A, Gelpi RJ, Morales C. Effects of the early administration of losartan on the functional and morphological aspects of postmyocardial infarction ventricular remodeling in rabbits. Cardiovasc Pathol 14: 88-95, 2005.
13. Graham HK, Trafford AW. Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. Am J Physiol Heart Circ Physiol 292: H1364-H1372, 2007.
14. Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 7: 223-253, 2005.
15. 1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 39: 401-412, 1998.
16. Jain M, Liao R, Ngoy S, Whittaker P, Apstein CS, Eberli FR. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. Cardiovasc Res 46: 66-72, 2000.
17. 1 receptor blockade. J Mol Cell Cardiol 37: 1023-1030, 2004.
18. Knoess M, Krukemeyer MG, Kriegsmann J, Thabe H, Otto M, Krenn V. Colocalization of C4d deposits/CD68+ macrophages in rheumatoid nodule and granuloma annulare: immunohistochemical evidence of a complement-mediated mechanism in fibrinoid necrosis. Pathol Res Pract 204: 373-378, 2008.
19. Laird JD, Vellekoop HP. The course of passive elasticity of myocardial tissue following experimental infarction in rabbits and its relation to mechanical dysfunction. Circ Res 41: 715-721, 1977.
20. + exchanger-mediated effect. Br J Pharmacol 147: 690-697, 2006.
21. Li Y, Takemura G, Okada H, Miyata S, Kanamori H, Maruyama R, Esaki M, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart. Am J Physiol Heart Circ Physiol 292: H946-H953, 2007.
22. Liu Y, Leri A, Li B, Wang X, Cheng W, Kajstura J, Anversa P. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes. Circ Res 82: 1145-1159, 1998.
23. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359: 2456-2467, 2008.
24. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS. Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol Heart Circ Physiol 279: H1534-H1539, 2000.
25. Morales C, Gonzalez GE, Rodriguez M, Bertolasi CA, Gelpi RJ. Histopathologic time course of myocardial infarct in rabbit hearts. Cardiovasc Pathol 11: 339-345, 2002.
26. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 367: 356-367, 2006.
27. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, Konstam MA. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 104: 109-118, 2003.
28. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De WF, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J 140: 727-750, 2000.
29. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000.
30. Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, Lapointe N, Tsoporis JN, Rouleau JL. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am J Physiol Heart Circ Physiol 288: H1997-H2005, 2005.
31. 1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 41: 100-108, 1999.
32. Sandmann S, Li J, Fritzenkotter C, Spormann J, Tiede K, Fischer JW, Unger T. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press 15: 116-128, 2006.
33. Shimizu T, Okamoto H, Chiba S, Matsui Y, Sugawara T, Akino M, Nan J, Kumamoto H, Onozuka H, Mikami T, Kitabatake A. VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts. Cardiovasc Res 58: 203-212, 2003.
34. Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther 17: 287-290, 2003.
35. Sugano Y, Anzai T, Yoshikawa T, Maekawa Y, Kohno T, Mahara K, Naito K, Ogawa S. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 65: 446-456, 2005.
36. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 30: 1559-1569, 1998.
37. 1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure. Am J Physiol Heart Circ Physiol 276: H1385-H1392, 1999.
38. 1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol Heart Circ Physiol 276: H873-H880, 1999.
39. van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp MA, Verdouw PD, Danser AH. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102: 1556-1563, 2000.
40. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 69: 604-613, 2006.
41. 1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res 49: 110-117, 2001.
42. Xu X, Wan W, Ji L, Lao S, Powers AS, Zhao W, Erikson JM, Zhang JQ. Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. Cardiovasc Res 78: 523-532, 2008.
43. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 25: 1369-1380, 1993.
44. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777-781, 2003.
45. Zdrojewski T, Gaudron P, Whittaker P, Poelzl S, Schiemann J, Hu K, Ertl G. Ventricular remodeling after myocardial infarction and effects of ACE inhibition on hemodynamics and scar formation in SHR. Cardiovasc Pathol 11: 88-93, 2002.